Linzagolix - Endometriosis

You are here : Home > Formulary Search > Linzagolix - Endometriosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative

Formulations :

Tablets

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

NFD2

SPC

Restrictions / Comments :

Documentation

No records returned.

PAD Profile

ChemicalSubstance :

Linzagolix

Indication :

Endometriosis

Group Name :

Keywords :

Brand Names Include :

Yselty

Important Information :

Not assessed for inclusion on the formulary. Contact pharmacy team for advice on making an application.

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Linzagolix is used to treat.

Uterine fibroids

Other Drugs

Below are listed other drugs that are used to treat Endometriosis.

Committee Recommendations (1)

04 Jun 25 - Not Set

This drug has not yet been assessed for formulary status for endometriosis.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug it is recommended that clinicians contact their Pharmacy / Medicines Optimisation team to discuss possible alternatives/options.

NICE published guidance on this drug in Jun 2025 and this will be considered by the APC within 90 days of publication.